Navigation Links
SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia

SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM) and GeneWorks Pty. Ltd. today announced an exclusive sales agency agreement under which GeneWorks will assist SEQUENOM in expanding its sales & marketing presence in Australia. The partnership will initially focus on new business development activity across Australia. GeneWorks has significant experience and a strong reputation in the supply of genomics technologies and reagents and is an Australian manufacturer of high quality oligonucleotides and offers a range of genetic analysis services including Next Generation Sequencing services.


"Given our introduction of the new MassARRAY Compact 96 system, OncoCarta oncogene mutation profiling panel, and our expansion into translational and clinical research sectors, we are excited about the capabilities that GeneWorks brings to assist us in expanding our customer base in Australia," said Mike Monko, senior vice president of sales & marketing at SEQUENOM. "Australia remains a key market for us in the Asia Pacific region and with our ongoing direct presence in Australia through our Asia Pacific office based in Queensland, we expect to see substantial business growth in this region over the coming years."

Peter Guilhaus, managing director of GeneWorks added, "We're excited and pleased to be partnering with SEQUENOM in Australia. SEQUENOM's MassARRAY system and related kits complement our product and services portfolio nicely. We're looking forward to supporting this powerful technology, and in conjunction with our oligo and genome analysis services, providing our customers with a comprehensive solution to their research needs."


SEQUENOM, Inc. (Nasdaq: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. SEQUENOM develops innovative technology, products and diagnostic tests that target and serve discovery & clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. SEQUENOM maintains a Web site at to which SEQUENOM regularly posts copies of its press releases as well as additional information about SEQUENOM. Interested persons can subscribe on the SEQUENOM Web site to email alerts or RSS feeds that are sent automatically when SEQUENOM issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM(R), OncoCarta(TM) and MassARRAY(R) are trademarks of SEQUENOM, Inc. All other trademarks and service marks are the property of their respective owners.

About GeneWorks

GeneWorks Pty. Ltd. established in 1996 is a major Australian supplier of leading edge molecular biology research products. Centrally headquartered in Adelaide, South Australia with sales offices in all Australian capital cities as well as Auckland NZ, it services and supplies the Australian and New Zealand markets with a select range of innovative leading edge equipment, reagents, consumables and associated services. Our core business is the synthesis and supply of custom oligonucleotides and next generation Genome Analysis Services. GeneWorks has implemented and maintains a quality management system and is ISO 9001:2008 certified. Our highly qualified staff are motivated to provide the highest possible level of professionalism and support of our products and services, allowing researchers to achieve their goals with maximum efficiency, reliability and confidentiality.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company expanding its sales and marketing presence and customer base in Australia, the Company's expectation of substantial business growth in Australia over the coming years, the performance of the MassARRAY Compact 96 system, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MassARRAY Compact 96 system, the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal and other diagnostic tests and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, the independent investigation and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
2. SEQUENOM Announces Launch of MassARRAY Compact 96 System
3. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
4. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
6. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
7. Misonix Announces New Sales Agency Agreement for Middle East, India and Pakistan
8. Simbionix USA Corporation Announces the Appointment of Mr. Paul Jensen as General Manager for its Growing eLearning and Content Business
9. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
10. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
11. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
(Date:11/24/2015)... ... November 24, 2015 , ... In ... paramount. Insertion points for in-line sensors can represent a weak spot where leaking ... 781/784 series of retractable sensor housings , which are designed to tolerate extreme ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):